A comparison of healthcare resource utilization and costs between patients with chronic lymphocytic leukemia treated with first-line ibrutinib or acalabrutinib using two large US real-world databases

A comparison of healthcare resource utilization and costs between patients with chronic lymphocytic leukemia treated with first-line ibrutinib or acalabrutinib using two large US real-world databases

Aim: Real-world evidence comparing healthcare resource utilization (HRU) and costs between ibrutinib and acalabrutinib, two Bruton’s tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL) is limited. Materials & methods: Commercial...

Full description

Saved in:
Bibliographic Details
Main Authors: Kerry A Rogers, Benyam Muluneh, Zaina P Qureshi, Jinghua He, Alex Bokun, Zhijie Ding, Marie-Helene Lafeuille, Priyanka Gogna, Bruno Emond, Michael Fradley
Format: Article
Language:English
Published: Becaris Publishing Limited 2025-04-01
Series:Journal of Comparative Effectiveness Research
Subjects:
acalabrutinib
chronic lymphocytic leukemia
claims data
cost comparison
costs
emr
healthcare resource use
ibrutinib
real-world study
small lymphocytic lymphoma
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items